drugset / Trial / NCT02977364
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment. The dose of HS-10241 will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of HS-10241 in advanced cancer patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of HS-10241 will be observed in advanced cancer patients. To determine the recommended dosage regimen for phase II.
Timeline
- Start
- 2016-11
- Primary completion
- 2018-11
- Completion
- 2021-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10241 | Small molecule | 100 mg | — |
| Subject | HS-10241 | Small molecule | 200 mg | — |
| Subject | HS-10241 | Small molecule | 400 mg | — |
| Subject | HS-10241 | Small molecule | 600 mg | — |
| Subject | HS-10241 | Small molecule | 800 mg | — |
| Subject | HS-10241 | Small molecule | 1000 mg | — |